A phase 2, controlled, multi-center pilot study to evaluate the efficacy and safety of Deligoparin in subjects with retinal vein occlusion of recent onset.

开始日期2005-09-12

申办/合作机构-

NCT00033943 / Completed临床2/3期

A Multi-Center, Placebo-Controlled Evaluation of the Safety and Efficacy of Two Dosage Levels of OP2000 (75 Mg and 125 Mg) Administered Once Daily by Subcutaneous Injection for the Treatment of Active Ulcerative Colitis

This study will evaluate the effectiveness and safety of the experimental compound OP2000 (deligoparin) in patients with active ulcerative colitis. Patients eligible for this study will have received (and will continue to receive) stable doses of aminosalicylates (oral, enema and/or suppository), if tolerated. OP2000 is an ultra low molecular weight heparin with anticoagulant (blood thinning) and anti-inflammatory actions that may be of benefit for the treatment of ulcerative colitis.

开始日期2001-01-01

申办/合作机构

Incara Pharmaceuticals Corp.

100 项与 Deligoparin sodium 相关的临床结果

登录后查看更多信息

100 项与 Deligoparin sodium 相关的转化医学

登录后查看更多信息

100 项与 Deligoparin sodium 相关的专利（医药）

登录后查看更多信息

项与 Deligoparin sodium 相关的文献（医药）

1999-03-01·Clinical Cardiology3区 · 医学

Efficacy and tolerability of a very low molecular weight heparin compared with standard heparin in patients with unstable angina: A pilot study

3区 · 医学

ArticleOA

作者: L. Sormani ; Anna Vittoria Mattioli ; Emma Tarabini Castellani ; S. Sternieri ; L. Goedecke ; Giorgio Mattioli

BACKGROUNDUnstable angina is an active thrombotic process that involves thrombus formation and platelets. It requires a rapid and intensive treatment with anticoagulants and antiplatelets.HYPOTHESISThe aim of the present study was to compare the efficacy of a very low molecular weight heparin, OP 2000, with standard heparin in the treatment of unstable angina. Tolerance and safety were also assessed.METHODSThe study population included 120 consecutive hospitalized patients with unstable angina randomized for treatment with very low molecular weight heparin or with standard heparin. The dosage of the study drug was 200 mg intramuscular (i.m.) the first day followed by 150 mg IM/day. The control drug was standard heparin starting at a dosage of 5,000 UI/ml intravenously (i.v.) and followed by continuous infusion at an activated partial thromboplastin time-adjusted dosage. The primary end points were death, acute myocardial infarction, urgent revascularization, and recurrence of angina. Tolerability was assessed using bleeding parameters, thrombocytopenia, and allergic reactions.RESULTSFourteen clinical events were reported in the study group compared with 25 events in the control group (p < 0.05). No adverse events were reported in either group.CONCLUSIONDuring the acute phase of unstable angina, treatment with a very low molecular weight heparin plus aspirin was more effective than treatment with standard heparin plus aspirin.

100 项与 Deligoparin sodium 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D03673	-	-	-

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
活动性重度溃疡性结肠炎	临床3期	美国	Incara Pharmaceuticals Corp.	2001-01-01
溃疡性结肠炎	临床3期	-	Aeolus Pharmaceuticals, Inc.	-
溃疡性结肠炎	临床3期	-	Perrigo Co. Plc	-
溃疡性结肠炎	临床3期	-	Opocrin SpA	-
溃疡性结肠炎	临床3期	-	Perrigo Co. Plc	-
溃疡性结肠炎	临床3期	-	Opocrin SpA	-
溃疡性结肠炎	临床3期	-	Aeolus Pharmaceuticals, Inc.	-